Evidence map›Paper›PMID 38883797›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in presence of CD4-mimetics.

Alexandra Tauzin, Lorie Marchitto, Étienne Bélanger, Mehdi Benlarbi, Guillaume Beaudoin-Bussières, Jérémie Prévost, Derek Yang, Ta-Jung Chiu, Hung-Ching Chen, Catherine Bourassa and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Alexandra TauzinCentre de Recherche du CHUM, Montreal, QC, Canada.
Lorie MarchittoCentre de Recherche du CHUM, Montreal, QC, Canada.
Étienne BélangerCentre de Recherche du CHUM, Montreal, QC, Canada.
Mehdi BenlarbiCentre de Recherche du CHUM, Montreal, QC, Canada.
Guillaume Beaudoin-BussièresCentre de Recherche du CHUM, Montreal, QC, Canada.
Jérémie PrévostCentre de Recherche du CHUM, Montreal, QC, Canada.
Derek YangDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Ta-Jung ChiuDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Hung-Ching ChenDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Catherine BourassaCentre de Recherche du CHUM, Montreal, QC, Canada.
Halima MedjahedCentre de Recherche du CHUM, Montreal, QC, Canada.
Marek K KorzeniowskiInfectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Suneetha GottumukkalaInfectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
William D TolbertInfectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Jonathan RichardCentre de Recherche du CHUM, Montreal, QC, Canada.
Amos B SmithDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Marzena PazgierInfectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Andrés FinziCentre de Recherche du CHUM, Montreal, QC, Canada.

Funding

ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Exploring HIV-1 Env open conformations for therapeutic interventionR01AI150322 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Andres Finzi, James B Munro · 2020 to 2026
$4.2M
Identifying vulnerabilities in the long-lived HIV reservoir to accelerate its decayR01AI176531 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Nicolas Chomont, ANN C DUERR · 2023 to 2026
$4.1M
Assessing ADCC and Fc-mediated Protection against HIVR01AI148379 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T, FINZI, ANDRES · 2019 to 2023
$3.8M
A new strategy to eliminate HIV-1-infected cells by unlocking the Env trimerR01AI174908 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI Marzena Elzbieta Pazgier · 2023 to 2026
$2.8M
Unlocking Envelope: A New Strategy for a Functional Cure Through Antibody-Dependent Cell-Mediated CytotoxicityR01AI129769 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZGIER, MARZENA ELZBIETA · 2017 to 2021
$2.3M
NIAID NIH HHS R01 AI129769NIAID NIH HHS R01 AI148379NIAID NIH HHS R01 AI150322NIAID NIH HHS R01 AI174908NIAID NIH HHS R01 AI176531NIAID NIH HHS UM1 AI164562
6 · The paper itself

Abstract

CD4-mimetics (CD4mcs) are small molecule compounds that mimic the interaction of the CD4 receptor with HIV-1 envelope glycoproteins (Env). Env from primary viruses normally samples a "closed" conformation which occludes epitopes recognized by CD4-induced (CD4i) non-neutralizing antibodies (nnAbs). CD4mcs induce conformational changes on Env resulting in the exposure of these otherwise inaccessible epitopes. Here we evaluated the capacity of plasma from a cohort of 50 people living with HIV to recognize HIV-1-infected cells and eliminate them by antibody-dependent cellular cytotoxicity (ADCC) in the presence of a potent indoline CD4mc. We observed a marked heterogeneity among plasma samples. By measuring the levels of different families of CD4i Abs, we found that the levels of anti-cluster A, anti-coreceptor binding site and anti-gp41 cluster I antibodies are responsible for plasma-mediated ADCC in presence of CD4mc.

Identifiers

PMID38883797
PMCPMC11177920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.